Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program
If you're currently on a prescription GLP-1 injection and you're thinking about switching, please speak to your healthcare provider first
doi: 10.1038/304368a0 7 HolstJJOrskovCNielsenOVSchwartzTW
#Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
Adjusting the dose and monitoring progress helps ensure the treatment is effective
Even moderate doses (8 mg) led to ~2223% weight loss, highlighting a dose-responsive effect
